Patent US3968245A successfully refreshed from Google Patents.
US3968245A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Sympathomimetic topical and percutaneous administration with halogenated promoters
Assignee: Alza Corp
•
Filing: 1975-05-01
•
Granted: 1976-07-06
•
Expires: 1995-05-01
Abstract
Abstract Dermal compositions are disclosed with comprise trichloroethanol or trifluoroethanol as one component of a vehicle having solubilized therein a drug or other beneficial chemical compound. Also disclosed is a method for administering a drug or other beneficial chemical compound to the body which comprises contacting the skin with the drug or compound in the presence of trichloroethanol or trifluoroethanol which acts as an absorption promoter to enhance the topical or percutaneous absorption of the active drug or compound.
Inventors
- 👤 Takeru Higuchi
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-04 21:54
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/0014; A61K47/00; A61K47/06; A61K47/08; A61K47/10
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
74 words
A pharmaceutical composition of matter comprising a first ingredient selected from the group of pharmaceutically acceptable topical and percutaneous absorption promoters consisting of trichloroethanol, trifluoroethanol and mixtures thereof, and about 0.01 to 30% of at least one local, topically administered sympathomimetic drug as a second ingredient, and wherein when topically administered, the first ingredient is a promoter for increasing topical retention and percutaneous absorption of a therapeutically effective amount of the second sympathomimetic ingredient.
Claim 2
Dependent Claim
74 words
A pharmaceutical composition of matter comprising a first ingredient selected from the group of pharmaceutically acceptable topical and percutaneous absorption promoters consisting of trichloroethanol, trifluoroethanol and mixtures thereof, and about 0.01 to 30% of at least one local, topically administered sympathomimetic drug as a second ingredient, and wherein when topically administered, the first ingredient is a promoter for increasing topical retention and percutaneous absorption of a therapeutically effective amount of the second sympathomimetic ingredient.
Claim 3
Dependent Claim
52 words
The pharmaceutical composition of matter according to claim 1 wherein the sympathomimetic drug is a member selected from the group consisting of amphetamine, amphetamine sulfate, benzphetamine hydrochloride, cyclopentamine hydrochloride, dextroamphetamine hydrochloride, diethylpropion hydrochloride, ephedrine, ephedrine hydrochloride, epinephrine, epinephrine bitartrate, hydroxyamphetamine hydrobromide, isoproternol sulfate, isosupine hydrochloride, methamphetamine hydrochloride, methoxyamine hydrochloride, and phenylephrine hydrochloride.
Claim 4
Dependent Claim
21 words
The pharmaceutical composition of matter according to claim 1 wherein the sympathomimetic drug has a molecular weight of 130 to 560.
Claim 5
Dependent Claim
108 words
In a method for producing a local, topical sympathomimetic effect, the improvement consisting in the step of administering cutaneously a pharmaceutical composition consisting of a first ingredient selected from the group of topical absorption promoters consisting of trichloroethanol, trifluoroethanol and mixtures thereof, and a second ingredient consisting of about 0.01 to 30% by weight of a sympathomimetic drug selected from the group consisting of amphetamine, benzphetamine, cyclopentamine, dextroamphetamine, diethylpropion, ephedrine, epinephrine, hydroxyamphetamine, isoproterenol, isosupine, methamphetamine, methoxamine, and pehnylephrine, and wherein the first ingredient is an absorption promoter for increasing the retention and percutaneous absorption of a therapeutically effective amount of the second ingredient during the topical administration thereof.
Claim 6
Dependent Claim
108 words
In a method for producing a local, topical sympathomimetic effect, the improvement consisting in the step of administering cutaneously a pharmaceutical composition consisting of a first ingredient selected from the group of topical absorption promoters consisting of trichloroethanol, trifluoroethanol and mixtures thereof, and a second ingredient consisting of about 0.01 to 30% by weight of a sympathomimetic drug selected from the group consisting of amphetamine, benzphetamine, cyclopentamine, dextroamphetamine, diethylpropion, ephedrine, epinephrine, hydroxyamphetamine, isoproterenol, isosupine, methamphetamine, methoxamine, and pehnylephrine, and wherein the first ingredient is an absorption promoter for increasing the retention and percutaneous absorption of a therapeutically effective amount of the second ingredient during the topical administration thereof.
Claim 7
Dependent Claim
34 words
In a method for producing a local sympathomimetic effect according to claim 4 wherein the pharmaceutical composition contains 0.01 to 99.99% of the first ingredient and from 0.01 to 30% of the second ingredient.
Claim 8
Dependent Claim
22 words
In a method for producing a local sympathomimetic effect according to claim 4 wherein the pharmaceutical composition contains a pharmaceutically acceptable carrier.
References Cited (Backward Citations)
US3787571A
Cited
US3891757A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1979-07-06 | 1980-01-05 | 1980-07-06 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1983-07-06 | 1984-01-05 | 1984-07-06 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1987-07-06 | 1988-01-05 | 1988-07-06 | $7700.00 | Window Closed / Lapsed |